Funding Opportunities

The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.

Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding.

Request for Proposals (Contracts)

Title Fast-Track Proposals Direct-to-Phase II Proposals Receipt date Anticipated Awards Budget

NIH/NCI 459 – Automated Software for Point-of-Care Testing to Identify Cancer-Associated Malnutrition

 Accepted NOT Accepted 11/14/2023 2-3 Phase I: up to $400,000 for up to 12 months
Phase II: up to $2,000,000 for up to 2 years

NIH/NCI 456– Rapid and Affordable Point-of-Care HPV Diagnostics for Cervical Cancer Control

 Accepted Accepted 11/14/2023 3-5 Phase I: up to $400,000 for up to 12 months
Phase II: up to $2,000,000 for up to 2 years

Notice of Funding Opportunities

Title Announcement Number Activity Code Clinical Trials Status Expiration Date Program Official
HEAL Initiative Partnerships to Advance INterdisciplinary (PAIN) Training in Clinical Pain Research: The HEAL PAIN Cohort Program RFA-NS-24-015 (T90/R90 Independent Clinical Trial Not Allowed) R90, T90 Clinical Trial Not Allowed 09/27/2023 Rachel Altshuler, Ph.D.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-20-313 (UH2/UH3 Clinical Trial Not Allowed) UH2, UH3 Clinical Trial Not Allowed 10/11/2023 Lynn Sorbara, Ph.D.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-20-314 (UH3 Clinical Trials Not Allowed) UH3 10/11/2023 Lynn Sorbara, Ph.D.
HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] RFA-NS-22-052 (U19 Clinical Trial Not Allowed) U19 Clinical Trial Not Allowed 10/11/2023 Rachel Altshuler, Ph.D.
Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health RFA-CA-24-005 (U01 Clinical Trial Optional) U01 Clinical Trial Optional 10/14/2023 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
HEAL Initiative: Toward Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required) RFA-AT-24-003 Clinical Trial Required 10/19/2023
HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics RFA-NS-24-018 (UG3/UH3 Clinical Trial Optional) UH3, UG3 Clinical Trial Optional 10/24/2023
HEAL Initiative: HEAL KIDS (Knowledge, Innovation and Discovery Studies) Pain: Acute Pain Clinical Trials Program RFA-HD-24-011 (U01 Clinical Trial Required) U01 Clinical Trial Required 11/21/2023 Brennan Streck, Ph.D., R.N., M.P.H.
Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries RFA-CA-23-033 (U01 Clinical Trial Optional) U01 Clinical Trial Optional 12/16/2023 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Stephen I. Katz Early Stage Investigator Research Project Grant PAR-21-039 (R01 Basic Experimental Studies with Humans Required) R01 12/29/2023